Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review
Franchesca Choi, Christina N. Kraus, Ashley Elsensohn, et al.
Journal of the American Academy of Dermatology (2019) Vol. 82, Iss. 2, pp. 440-459
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Immune checkpoint inhibitors to treat cutaneous malignancies
Dulce M. Barrios, H. Mytrang, Gregory S. Phillips, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 5, pp. 1239-1253
Open Access | Times Cited: 78
Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy
Evan Hall, Elena Fernández‐López, Ann W. Silk, et al.
American Society of Clinical Oncology Educational Book (2020), Iss. 40, pp. 398-407
Open Access | Times Cited: 59
Non-melanoma skin cancers: physio-pathology and role of lipid delivery systems in new chemotherapeutic treatments
Eliana B. Souto, Raquel da Ana, Vânia Vieira, et al.
Neoplasia (2022) Vol. 30, pp. 100810-100810
Open Access | Times Cited: 29
Current knowledge of immunosuppression as a risk factor for skin cancer development
María Paz Rollán, Raúl Cabrera, Robert A. Schwartz
Critical Reviews in Oncology/Hematology (2022) Vol. 177, pp. 103754-103754
Closed Access | Times Cited: 29
Comparative Efficacy of Cemiplimab Versus Other Systemic Treatments for Advanced Cutaneous Squamous Cell Carcinoma
Sam Keeping, Yingxin Xu, Chieh-I Chen, et al.
Future Oncology (2020) Vol. 17, Iss. 5, pp. 611-627
Open Access | Times Cited: 48
Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma
Enrico Zelin, Iris Zalaudek, Marina Agozzino, et al.
Current Treatment Options in Oncology (2021) Vol. 22, Iss. 4
Open Access | Times Cited: 37
Known and new facts on basal cell carcinoma
Magdalena Seidl‐Philipp, Nina Frischhut, Nicole Höllweger, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2021) Vol. 19, Iss. 7, pp. 1021-1041
Open Access | Times Cited: 37
Site-Specific Vesicular Drug Delivery System for Skin Cancer: A Novel Approach for Targeting
Manisha Pandey, Hira Choudhury, Bapi Gorain, et al.
Gels (2021) Vol. 7, Iss. 4, pp. 218-218
Open Access | Times Cited: 35
Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response
Enrico Zelin, Carlo Alberto Maronese, Arianna Dri, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 12, pp. 3364-3364
Open Access | Times Cited: 27
Evolving Role of Systemic Therapies in Non-melanoma Skin Cancer
Claudio Conforti, Paola Corneli, Catherine Α. Harwood, et al.
Clinical Oncology (2019) Vol. 31, Iss. 11, pp. 759-768
Closed Access | Times Cited: 34
Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma
Nicholas Frazzette, Alireza Khodadadi‐Jamayran, Nicole Doudican, et al.
npj Precision Oncology (2020) Vol. 4, Iss. 1
Open Access | Times Cited: 28
Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment
Clio Dessinioti, Alexander J. Stratigos
Dermatology Practical & Conceptual (2023), pp. e2023252-e2023252
Open Access | Times Cited: 10
Cemiplimab for locally advanced and metastatic basal cell carcinoma
Thomas Damsin, Eve Lebas, Nathalie Marchal, et al.
Expert Review of Anticancer Therapy (2022) Vol. 22, Iss. 3, pp. 243-248
Closed Access | Times Cited: 13
Molecular pathways and therapeutic strategies in dermatofibrosarcoma protuberans (DFSP): unravelling the tumor's genetic landscape.
Harpreet Singh, Heena Bholaram Choudhary, Deepa S. Mandlik, et al.
PubMed (2024) Vol. 23, pp. 727-762
Closed Access | Times Cited: 2
PD-L1 expression in sebaceous carcinomas
Maelle Saliba, Muhammad Shaheen, Rana El Hajj, et al.
Cancer Immunology Immunotherapy (2021) Vol. 70, Iss. 7, pp. 1907-1915
Closed Access | Times Cited: 14
Treatment of Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitors: A Multidisciplinary Expert Meeting
Vincenzo De Giorgi, Federica Scarfì, Luciana Trane, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5706-5706
Open Access | Times Cited: 14
Recent advances in Merkel cell carcinoma
Caitlin G. Robinson, Daniel Shao-Weng Tan, Siegrid S. Yu
F1000Research (2019) Vol. 8, pp. 1995-1995
Open Access | Times Cited: 15
Recent and Emerging Therapies for Cutaneous Squamous Cell Carcinomas of the Head and Neck
Vamsi Varra, Timothy D. Smile, J.L. Geiger, et al.
Current Treatment Options in Oncology (2020) Vol. 21, Iss. 5
Closed Access | Times Cited: 12
Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series
Katherine Given Ligtenberg, Jamie K. Hu, William Damsky, et al.
JAAD Case Reports (2020) Vol. 6, Iss. 7, pp. 628-633
Open Access | Times Cited: 12
New Developments in the Management of Cutaneous Squamous Cell Carcinoma
Thomas Knackstedt, Rebecca Knackstedt, Michelle Djohan, et al.
Plastic & Reconstructive Surgery (2021) Vol. 147, Iss. 3, pp. 492-504
Closed Access | Times Cited: 10
Differential Molecular Expression Patterns Associated with Metastasis in Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
Patrick M. Mulvaney, Paul R. Massey, Kenneth K. Yu, et al.
Journal of Investigative Dermatology (2021) Vol. 141, Iss. 9, pp. 2161-2169
Open Access | Times Cited: 10
The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma
Morgan Guénolé, Paolo Bénigni, Vincent Bourbonne, et al.
Journal of Cancer Research and Clinical Oncology (2021) Vol. 147, Iss. 9, pp. 2569-2578
Closed Access | Times Cited: 10
Epidermal Growth Factor Receptor’s Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies
Priscila Oliveira de Lima, Shannon R. Joseph, Benedict Panizza, et al.
Current Treatment Options in Oncology (2020) Vol. 21, Iss. 1
Closed Access | Times Cited: 10
Basal cell carcinoma: Management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors
Philip R Cohen, Razelle Kurzrock
Journal of the American Academy of Dermatology (2020) Vol. 82, Iss. 6, pp. e253-e254
Open Access | Times Cited: 10
Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer
Reason Wilken, Maressa C. Criscito, Anna C. Pavlick, et al.
Facial Plastic Surgery (2020) Vol. 36, Iss. 02, pp. 200-210
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top